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 Introduction 
 Few dermatological complaints carry as much emo-
tional overtones as hair loss. Frequently encountered in 
dermatological practice is the woman who is ‘losing her 
hair’. Many factors can lead to pathologically increased 
hair loss. A definitive diagnosis can usually be estab-
lished, particularly focussing on the chronology of pre-
ceding events, examination of the scalp, pattern of hair 
loss, results of the pull test, examination of the bulbs of 
the shed hairs and a few pertinent screening blood tests 
 [1] . In most patients presenting in clinical practice, hair 
loss results from an increase in the percentage of follicles 
in the telogen phase with subsequent increased shedding 
of the associated club hairs (telogen effluvium). Once the 
diagnosis is established, treatment appropriate for that 
diagnosis is likely to control the hair loss, e.g. iron defi-
ciency, other dietary deficiencies, thyroid disease, other 
metabolic or endocrine diseases, systemic lupus erythe-
matosus, other connective tissue disorders, syphilis, oth-
er chronic infectious diseases, and drug-induced telogen 
effluvium.
 In otherwise healthy women, female-pattern hair loss 
(FPHL) is the most frequent cause of telogen effluvium 
and is usually successfully treated with topical minoxidil 
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 Abstract 
 Background: A number of otherwise healthy women with 
or without clinical alopecia complain of recurrent hair loss, 
presumably reflecting seasonality in the growth and shed-
ding of hair.  Objective: To test the hypothesis that periodic-
ity in hair shedding reflects seasonal changes in human hair 
growth.  Methods: Retrospective case study over a period of 
6 years of apparently healthy women with the complaint of 
hair loss. All underwent biochemical investigations, and 
trichograms were made.  Results: After exclusion of patients 
with a disease or on drugs known to cause hair loss, 823 
women remained. Analysis of trichograms demonstrated 
annual periodicity in the growth and shedding of hair, man-
ifested by a maximal proportion of telogen hairs in summer. 
A second peak seems to exist, though it is less pronounced, 
in spring. The telogen rates were lowest in late winter.  Con-
clusions: These results confirm the findings of former au-
thors who have indicated seasonal changes in human hair 
growth, though this is the first study performed systemati-
cally in a representative number of women. 
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 [2–4] . Special attention is also given to the use of a con-
traceptive pill or hormonal replacement therapy, since 
gestagens with proandrogenic effect may exacerbate hair 
loss and are consequently contraindicated in these wom-
en. Some authors eventually recommend the use of anti-
androgen therapy, such as cyproterone acetate  [5] , spi-
ronolactone  [5, 6] or finasteride  [7] , though there exists 
controversy on this issue  [8–10] . Nevertheless, a number 
of women complain of recurrent hair loss, despite at times 
successful therapy. The condition tends to run a fluctuat-
ing course, presumably reflecting seasonal periodicity in 
the growth and shedding of hair.
 To test the hypothesis that periodicity in shedding of 
hairs in otherwise healthy women complaining of hair 
loss reflects seasonal changes in human hair growth, we 
performed a study of telogen rates in relation to the sea-
son as assessed by the trichogram technique.
 Patients and Methods 
 Telogen rates as assessed by the trichogram technique for eval-
uation of hair loss in women presenting at the Department of 
Dermatology, University Hospital of Zurich hair clinic, were col-
lected between September 1, 2001, and August 31, 2007. For the 
trichogram, all patients had at least 50 hairs plucked from sam-
pling sites on the frontal and occipital scalp, using a tightly closing 
epilation forceps. Uniformly, patients were instructed to leave 
their hair unwashed and untreated with any cosmetics for 5 days 
prior to the plucking of the hairs for the trichogram. Immedi-
ately after epilation, the hair roots were embedded in Histokitt TM 
mounting medium which had previously been spread onto a glass 
slide for light microscopy. The hair roots were arranged neatly in 
juxtaposition and covered with a coverslip. Quantification of the 
different hair roots on the basis of their morphological character-
istics relating to the hair cycle was performed by the same inves-
tigator.
 In all women, a careful history of systemic disease or drugs 
known to cause hair loss was obtained. Biochemical investiga-
tions included thyroid function tests, C-reactive protein and se-
rum ferritin levels in all patients, renal and liver function tests, 
hormonal and extended nutritional studies in selected cases, as 
indicated by the patient history, clinical and trichogram findings. 
Serum levels of ferritin  1 40   g/l, vitamin B 12 300–1,000 ng/l, fo-
lic acid 5–40 nM, estradiol (day 21)  1 300 pM and progesterone 
(day 21)  1 30 nM were considered normal  [11] .
 Trichograms were included irrespective of the presence or not 
of clinically appreciable alopecia. Patients with alopecia areata or 
scarring alopecia were excluded. FPHL was diagnosed either clin-
ically (Ludwig patterns I–III with or without pathological tricho-
gram) or on the basis of a trichogram with a frontal telogen rate 
 1 15% and an occipital telogen rate  ! 15%, diffuse telogen efflu-
vium was diagnosed when the occipital telogen rate was above 
15%. Patients with dystrophic effluvium ( 1 10% dystrophic ana-
gen hairs) were excluded. The trichograms were either made on 
the occasion of the initial visit, without treatment, or at least 6 
months after introduction of topical 2% minoxidil therapy in 
women with FPHL complaining of hair loss (control tricho-
gram).
 Statistical Analysis 
 Telogen rates were analyzed with respect to seasonal fluctua-
tions in relation to the period of the year. We also wanted to find 
out whether telogen rates in relation to the period of the year de-
pended on patient age, and whether there were differences be-
tween the single years from 2001 to 2007.
 The function GAM (generalized additive model) in the pack-
age MGCV of the statistical program R (http://www.r-project.
org/) was used for statistical analyses and plots. MGCV means 
‘GAMs with GCV smoothness estimation and GAMMs by 
REML/PQL’ and GAM means ‘generalized additive models with 
integrated smoothness estimation’. Smooth terms are represented 
using penalized regression splines with smoothing parameters 
selected by GCV/UBRE. Wald tests were performed for the anal-
ysis of parametric and smooth terms. p  ! 0.05 was considered 
statistically significant.
 Results 
After exclusion of patients with a history of systemic 
disease or on drugs known to cause hair loss, with abnor-
mal laboratory investigations, alopecia areata or scarring 
alopecia, 823 otherwise healthy women remained. The 
mean age of the total group of 823 women was 44.3 years 
(range: 18–78;  fig. 1 ).
The mean frontal telogen rate was 18.1% (range: 1–70), 
and the mean occipital telogen rate was 18.1% (range: 1–
74). The number of women with FPHL was 652 (79.2%), 
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 Fig. 1. Distribution of case counts by age. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
6/
20
16
 5
:3
8:
28
 P
M
 Seasonality of Hair Shedding Dermatology 2009;219:105–110 107
with a mean age of 44.5 years (range: 18–78). In this 
group, the mean frontal telogen rate was 18.1% (range: 
1–53). The mean occipital telogen rate in patients with 
FPHL was 17.6% (range: 2–73), reflecting a frequent com-
bination of FPHL with telogen effluvium. Telogen rates 
did not significantly depend on patient age ( fig. 2 ) and 
year (data not shown).
Telogen rates by month of the year showed an overall 
annual periodicity, manifested by a maximal proportion 
of telogen hair in July. A second peak seems to exist, al-
though less pronounced, in April ( fig. 3 ). Fluctuations in 
telogen rates in relation to the day of the year were found 
to be highly significant (p  ! 0.001;  fig. 4 ). This was re-
flected in subsequent clinical images taken of patients 
( fig. 5 ). When frontal telogen rates in relation to the pe-
riod of the year of women with FPHL were separately 
analyzed, the fluctuations in telogen rates were practi-
cally identical to the total group of women.
 Discussion 
 The hair follicle is subject to constant turnover in the 
course of perpetual cycles through phases of proliferation 
(anagen), involution (catagen) and resting (telogen), with 
regeneration in the successive hair cycle. In the telogen 
phase, the hair shaft matures into a club hair, which is 
held tightly in the bulbous base of the follicular epitheli-
um, before it is eventually shed (teloptosis)  [12, 13] . There 
are considerable variations in length of these phases de-
pending on the body site location, with the duration of 
the anagen phase determining the length of the produced 
hair fiber and the percentage of growing hairs. On the 
scalp, hairs remain in the anagen phase for a 2- to 6-year 
period of time, whereas that of telogen is approximately 
100 days, resulting in a ratio of anagen to telogen hairs of 
9: 1. Cyclic hair growth activity occurs in a random mo-
saic pattern so that on average, the amount of new scalp 
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 Fig. 2. No fluctuation in frontal telogen rate in relation to patient 
age. 
 Fig. 3. Means of frontal telogen rates in percent, with their stan-
dard deviations, by month of the year (n = 823). 
 Fig. 4. Fluctuations in frontal telogen rates (n = 823) in relation to 
the day of the year. 
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hair formation matches the amount that is shed, thereby 
maintaining a consistent covering.
 Each follicle possesses its own individual control 
mechanism over the evolution and triggering of the suc-
cessive phases, though systemic factors, such as the hor-
monal system, cytokines and growth factors, as well as 
external factors linked to the environment, toxins, defi-
ciencies of nutrients, vitamins and energy, have influ-
ence. In general, the pathological dynamics of hair loss 
can be related to disorders of hair cycling  [14] . Whatever 
the cause, the follicle tends to behave in a similar way, 
with telogen effluvium representing the most frequent 
cause of hair loss  [15] . Headington  [16]  proposed a clas-
sification of telogen effluvium into different functional 
types based on changes in the different phases of the hair 
cycle. Basically, telogen effluvium results from synchro-
nization phenomena of the hair cycle resulting in in-
creased shedding of hairs from the telogen phase of the 
cycle, or from shortening of the duration of the anagen 
phase (without synchronization) underlying androgenet-
ic alopecia.
 Headington  [16] proposed that a delayed telogen re-
lease underlies moulting in mammals, and possibly mild 
telogen effluvia following travel from low-daylight to 
high-daylight conditions. In this case, hair follicles re-
main in a prolonged telogen phase rather than being shed 
and recycling into anagen. When finally teloptosis sets in, 
again the clinical sign of increased shedding of club hairs 
is observed.
 Different methods have been adapted for identifica-
tion and quantification of hair loss. Of these, the tricho-
gram is the first technique standardized for this purpose 
and is routinely used at our institution for diagnostic pur-
poses in women complaining of hair loss. Initially devel-
oped in 1975 by van Scott’s group, subsequently other au-
thors modified and standardized the technique defining 
uniform and strict criteria for reliably assessing the dif-
ferent morphological hair root structures to ensure com-
parable results  [17, 18] . Telogen rates of 10–15% (max. 
20%) are considered normal in the adult scalp.
 Our study of 823 otherwise healthy women with telo-
gen effluvium presenting between September 1, 2001, 
and August 31, 2007 (6 years), in the Hair Consultation 
Clinic of the University Hospital of Zurich Department 
of Dermatology demonstrated the existence of overall 
annual periodicity in the growth and shedding of hair, 
manifested by a maximal proportion of telogen hairs in 
July. Taking a telogen phase duration of approximately 
100 days into account, one would expect shedding of 
these hairs by autumn. A second peak seems to exist, al-
though less pronounced, in April. The telogen rate was 
lowest towards the beginning of February. These results 
confirm the findings of authors who have formerly dem-
onstrated seasonal changes in human hair growth, though 
this is the first study performed systematically in women: 
Orentreich  [19] reported 3 women in New York who ex-
perienced maximum hair loss in November. By studying 
a group of 14 men during 18 months, Randall and Ebling 
 Fig. 5. Subsequent images taken in January 2007, August 2007 and February 2008. 
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 [20] showed that the proportions of telogen hair and of 
hair shedding were maximal in September. Courtois et 
al.  [21] observed 10 men, with or without alopecia, for a 
period of between 8 and 14 years, and also demonstrated 
a maximal proportion of telogen hairs at the end of sum-
mer. Some subjects also exhibited a periodicity approxi-
mately corresponding to two annual peaks. Our observa-
tion of a far larger number of patients led to statistically 
more significant calculations of these variations. Since 
we did not perform the study in a prospective manner on 
a group of women who were followed for a certain period, 
but in women visiting our Department with the com-
plaint of hair loss over a period of 6 years, the finding of 
statistically significant signals of annual periodicity 
points to a more general phenomenon, irrespective of the 
presence of clinical FPHL or not, and irrespective of top-
ical minoxidil treatment. Accordingly, fluctuations of 
telogen rates in relation to the period of the year were 
practically identical in women with FPHL and in the total 
group of women. It is our experience that women with 
FPHL tend to complain more often of noticeable period-
icity of hair loss. Due to a reduction of the anagen phase, 
mathematically, synchronization phenomena can be ex-
pected to be more marked in women with FPHL. In these 
women, the seasonal hair loss may be as striking as to be-
come clinically apparent ( fig. 5 ). The wide range of telo-
gen rates from as low as 1% to as high as  1 70% is ex-
plained by extreme synchronization phenomena in the 
anagen or telogen phase, respectively, since systemic dis-
eases and alopecia areta were excluded.
 The cyclical activities of the hair follicle constitute the 
mechanism by which mammals change their coat of hair 
to meet the exigencies of growth, seasonal changes in the 
ambient environment and, perhaps, normal wear and 
tear. It seems likely that environmental factors, such as 
the photoperiod, are mediated through the optic pathway 
and the neuroendocrine system coat phenotype and 
function to photoperiod-dependent environmental 
changes. The fact that human hair follicles, just as those 
of other mammals, undergo cyclical activity and are in-
fluenced by hormones implies that human hair is not un-
affected by these phenomena. From an evolutionary point 
of view, the maintenance of the low winter level of hair 
shedding and the postponement of hair fall until the end 
of summer might, perhaps, be postulated as having a se-
lective advantage with respect to insulation of the head 
against the cold in winter, and protection of the scalp 
against the midday sun in summer.
 More importantly, the existence of seasonal fluctua-
tions in hair growth and shedding complicates the assess-
ment of pharmacological effects. Awareness of these fluc-
tuations is prerequisite to providing the correct cause and 
prognosis to the patient, ensuring patient compliance 
with therapy, but it also has potentially serious implica-
tions for investigations with new hair-growth-promoting 
agents: depending on the stage of periodicity in growth 
and shedding of hair for a particular subject, the hetero-
geneity of included subjects may be enough to distort the 
clinical efficacy results and the perceived benefit of an 
investigational agent. In the active stage of seasonal telo-
gen effluvium, the involved hair follicles would probably 
fail to respond to the therapeutic agent, which may cause 
a false-negative result. In the recovery stage, the increased 
amounts of spontaneously regrowing hair might be inter-
preted falsely as a positive result.
 In summary, this is the first study on seasonal chang-
es in hair growth performed in a representative number 
of otherwise healthy women with or without clinical 
FPHL complaining of hair loss, demonstrating a signifi-
cant seasonal periodicity in the growth and shedding of 
hair.
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